Jump to navigation Jump to search
Monoclonal antibody
TypeWhole antibody
SourceTemplate:Infobox drug/mab source
TargetEpCAM (17-1A)
Clinical data
Trade namesPanorex
ATC code
CAS Number
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
 ☒N☑Y (what is this?)  (verify)

WikiDoc Resources for Edrecolomab


Most recent articles on Edrecolomab

Most cited articles on Edrecolomab

Review articles on Edrecolomab

Articles on Edrecolomab in N Eng J Med, Lancet, BMJ


Powerpoint slides on Edrecolomab

Images of Edrecolomab

Photos of Edrecolomab

Podcasts & MP3s on Edrecolomab

Videos on Edrecolomab

Evidence Based Medicine

Cochrane Collaboration on Edrecolomab

Bandolier on Edrecolomab

TRIP on Edrecolomab

Clinical Trials

Ongoing Trials on Edrecolomab at Clinical Trials.gov

Trial results on Edrecolomab

Clinical Trials on Edrecolomab at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Edrecolomab

NICE Guidance on Edrecolomab


FDA on Edrecolomab

CDC on Edrecolomab


Books on Edrecolomab


Edrecolomab in the news

Be alerted to news on Edrecolomab

News trends on Edrecolomab


Blogs on Edrecolomab


Definitions of Edrecolomab

Patient Resources / Community

Patient resources on Edrecolomab

Discussion groups on Edrecolomab

Patient Handouts on Edrecolomab

Directions to Hospitals Treating Edrecolomab

Risk calculators and risk factors for Edrecolomab

Healthcare Provider Resources

Symptoms of Edrecolomab

Causes & Risk Factors for Edrecolomab

Diagnostic studies for Edrecolomab

Treatment of Edrecolomab

Continuing Medical Education (CME)

CME Programs on Edrecolomab


Edrecolomab en Espanol

Edrecolomab en Francais


Edrecolomab in the Marketplace

Patents on Edrecolomab

Experimental / Informatics

List of terms related to Edrecolomab

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Edrecolomab (MAb17-1A, trade name Panorex) is a mouse-derived monoclonal antibody targeting the cell-surface glycoprotein EpCAM (17-1A), which is expressed on epithelial tissues and on various carcinomas.

Preliminary studies had shown promise of a possible use in patients with stage III colorectal carcinoma (with metastasis to the lymph nodes).[1][2] However, when put to a phase III study (2,761 patients) it did not provide any benefit when compared to conventional chemotherapeutic agents.[3] No effect has been demonstrated for stage II (locally advanced cancer without spread to the lymph nodes) colon cancer.[4]

Edrecolomab was well tolerated in these studies and as such research has now concentrated on whether it can be of any use in other forms of cancer.


  1. Riethmüller G, Schneider-Gädicke E, Schlimok G et al. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group. Lancet. 1994;343(8907):1177-83. PMID 7909866
  2. Fields AL, Keller AM, Schwartzberg L et al. Edrecolomab (17-1A antibody) in combination with 5-fluorouracil based chemotherapy in the adjuvant treatment of stage III colon cancer: results of a randomised North American phase III study (abstract). Proc Am Soc Clin Oncol. 2002;21:128a.
  3. Punt CJ, Nagy A, Douillard JY et al. Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study. Lancet. 2002;360(9334):671-7. doi:10.1016/S0140-6736(02)09836-7 PMID 12241873
  4. Colacchio TA, Niedzwicki D, Compton C, et al. Phase III trial of adjuvant immunotherapy with MoAb 17-1A following resection for stage II adenocarcinoma of the colon (CALGB 9581). Proc Am Soc Clin Oncol. 2004;23:251a.